Biological
PGT-121 clinical trials
Also written PGT121.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
4 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 4
International AIDS Vaccine Initiative (2) · Boris Juelg, MD PhD (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Often tested with
Tested in the same studies.
PGDM1400 (2) · VRC07-523LS (2) · Ad26.Mos4.HIV (1) · Zinlirvimab (1)
Studies
Open first, then newest update. How each study uses PGT-121 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected AdultsCompletedPhase 1/2Boris Juelg, MD PhDNCT04983030Written as PGT121
- Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult ParticipantsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03928821Written as PGT121
- A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected AdultsCompletedPhase 1/2International AIDS Vaccine InitiativeNCT03721510Written as PGT121 + VRC07-523LS
- Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected AdultsCompletedPhase 1International AIDS Vaccine InitiativeNCT02960581Written as PGT121 3mg/kg IV